ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-07-23 18:00 |
ABIVAX: Bilan semestriel du contrat de liquidité au 30 juin 2024.
|
French | 178.9 KB | ||
| 2024-07-22 09:46 |
Franchissement de seuil
|
French | 271.2 KB | ||
| 2024-07-15 22:00 |
Abivax fournit une mise à jour opérationnelle et fait le point sur son programm…
|
French | 215.0 KB | ||
| 2024-07-15 22:00 |
Abivax Provides Operational and Key Program Update
|
English | 24.5 KB | ||
| 2024-06-28 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 96.8 KB | ||
| 2024-05-29 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 97.1 KB | ||
| 2024-05-08 08:30 |
Abivax announces presentation of four abstracts for obefazimod in ulcerative co…
|
English | 113.7 KB | ||
| 2024-05-08 08:30 |
Abivax annonce la présentation de quatre abstracts sur obefazimod dans la recto…
|
French | 147.7 KB | ||
| 2024-05-07 22:00 |
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Avai…
|
English | 119.2 KB | ||
| 2024-05-07 22:00 |
Abivax assemblée générale ordinaire annuelle et extraordinaire du 30 mai 2024 -…
|
French | 121.2 KB | ||
| 2024-04-30 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 96.5 KB | ||
| 2024-04-05 22:00 |
Abivax a déposé ses rapports financiers auprès des autorités de marchés financi…
|
French | 80.5 KB | ||
| 2024-04-05 22:00 |
Abivax publishes financial reports with the French and U.S. securities regulato…
|
English | 5.6 KB | ||
| 2024-04-05 19:37 |
ABIVAX URD 2024
|
French | 5.5 MB | ||
| 2024-04-05 19:37 |
ABIVAX URD 2024
|
French | 5.5 MB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
